Ocugen to Host Conference Call on Tuesday, April 2 at 8:30 A.M. ET to Provide Business Update with Certain Financials for the Year Ending 2023
01 avr. 2024 17h43 HE
|
Ocugen
MALVERN, Pa., April 01, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...
PRISM MarketView Spotlights Companies Leading the Charge in Liver Disease Treatment Following Landmark FDA Approval
18 mars 2024 14h37 HE
|
PRISM MarketView
PRISM MarketView Spotlights Companies Leading the Charge in Liver Disease Treatment Following Landmark FDA Approval
PRISM MarketView Spotlights Lipella Pharmaceuticals as it Seizes Opportunities in Rare Disease
07 mars 2024 15h23 HE
|
PRISM MarketView
PRISM MarketView Spotlights Lipella Pharmaceuticals as it Seizes Opportunities in Rare Disease
Increasing Incidence of Pancreatic Cancer Leading to a $6.85 Billion Dollar Market Size for New Treatments
05 mars 2024 08h30 HE
|
FN Media Group LLC
PALM BEACH, Fla., March 05, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - Pancreatic cancer is one of the leading causes of cancer death globally. The increasing incidence of this cancer...
Biopharmaceutical Fermentation Systems Market Projected to Reach USD 52.6 billion by 2031, with a CAGR of 9.5%: Report by Transparency Market Research Inc.
01 mars 2024 01h32 HE
|
Transparency Market Research
Wilmington, Delaware, United States, March 01, 2024 (GLOBE NEWSWIRE) -- Transparency Market Research Inc. - The global biopharmaceutical fermentation systems market is projected to grow at a CAGR of...
PRISM MarketView Highlights Work of Emerging Companies on Rare Disease Day
29 févr. 2024 09h54 HE
|
PRISM MarketView
PRISM MarketView Highlights Work of Emerging Companies on Rare Disease Day
Ocugen Clinical Showcase Webcast Now Available
28 févr. 2024 08h00 HE
|
Ocugen
MALVERN, Pa., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...
GCANRx Announces Completion of Preclinical Study for Neuropsychiatric Cannabinoid Therapy
27 févr. 2024 07h45 HE
|
The Greater Cannabis Company, Inc.
BALTIMORE, MD, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Greater Cannabis Company, Inc. (“GCANRx” or the “Company”) (OTC: GCAN) a biopharmaceutical company pioneering development of next generation...
Ocugen Chairman and CEO to present at Abu Dhabi Family Office Summit
26 févr. 2024 08h30 HE
|
Ocugen
MALVERN, Pa., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene...
Leading Independent Proxy Advisory Firm ISS Recommends Aeterna Zentaris and Ceapro Securityholders Vote FOR the Arrangement Agreement to Approve the Merger of Equals to Create a Diversified Biopharmaceutical Company
26 févr. 2024 07h30 HE
|
Aeterna Zentaris Inc
ISS states in its Aeterna Zentaris FOR recommendation that “on balance, the deal has strong strategic merit, third party solicitation was unable to generate any other actionable proposals, and...